Paroxysmal nocturnal hemoglobinuria

• Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti‐C5 therapy

  2026 HemaSphere article Immunology and Microbiology Complement system in diseases Open access

  0

  citations
• Clinical Profile, Humanistic and Economic Burden of Paroxysmal Nocturnal Hemoglobinuria in Patients Treated With C5 Inhibitors

  2026 eJHaem article Immunology and Microbiology Complement system in diseases Open access

  0

  citations
• Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations

  2025 Bone Marrow Transplantation article Medicine Hematopoietic Stem Cell Transplantation Open access

  50

  citations
• Pharmacokinetic characterization and exposure–response relationship of crovalimab in the COMMODORE 1, 2 and 3 and COMPOSER trials of patients with paroxysmal nocturnal haemoglobinuria

  2025 British Journal of Clinical Pharmacology article Immunology and Microbiology Complement system in diseases Open access

  10

  citations
• Moving toward Individual Treatment Goals with Pegcetacoplan in Patients with PNH and Impaired Bone Marrow Function

  2024 International Journal of Molecular Sciences article Immunology and Microbiology Complement system in diseases Open access

  4

  citations
• The efficacy and safety of eculizumab in patients and the role of C5 polymorphisms

  2024 Drug Discovery Today article Immunology and Microbiology Complement system in diseases Open access cited by 1 patent

  24

  citations
• Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors

  2024 PLoS ONE article Immunology and Microbiology Complement system in diseases Open access

  3

  citations
• Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor‐experienced patients with paroxysmal nocturnal hemoglobinuria

  2024 American Journal of Hematology article Immunology and Microbiology Complement system in diseases Open access

  52

  citations
• Safety and Efficacy of Pegcetacoplan in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria over 48 Weeks: 307 Open-Label Extension Study

  2024 Advances in Therapy article Immunology and Microbiology Complement system in diseases Open access

  20

  citations
• Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long‐term results from the phase I/II COMPOSER trial

  2023 European Journal Of Haematology article Immunology and Microbiology Complement system in diseases Open access

  20

  citations
• The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors: clinical outcomes and medical encounters from the patient perspective

  2022 Hematology article Immunology and Microbiology Complement system in diseases Open access

  12

  citations
• The burden of illness of patients with paroxysmal nocturnal haemoglobinuria receiving C5 inhibitors in France, Germany and the United Kingdom: Patient‐reported insights on symptoms and quality of life

  2022 European Journal Of Haematology article Immunology and Microbiology Complement system in diseases Open access

  38

  citations
• Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022

  2022 Bone Marrow Transplantation article Medicine Hematopoietic Stem Cell Transplantation Open access

  378

  citations
• Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria

  2022 Expert Opinion on Emerging Drugs article Immunology and Microbiology Complement system in diseases

  7

  citations
• How we(’ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future

  2021 British Journal of Haematology article Immunology and Microbiology Complement system in diseases Open access

  74

  citations
• Halting targeted and collateral damage to red blood cells by the complement system

  2021 Seminars in Immunopathology article Immunology and Microbiology Complement system in diseases Open access

  20

  citations
• One‐year outcomes from a phase 3 randomized trial of ravulizumab in adults with paroxysmal nocturnal hemoglobinuria who received prior eculizumab

  2020 European Journal Of Haematology article Immunology and Microbiology Complement system in diseases Open access

  36

  citations

17 results